| Direct Competitor Comparison | |
|---|
| VVUS | LLY | GSK | PFE | Industry |
|---|
| Market Cap: | 1.43B | 55.69B | 124.68B | 206.41B | 71.76B |
|---|
| Employees: | 121 | 38,350 | 99,488 | 89,400 | 450.00 |
|---|
| Qtrly Rev Growth (yoy): | N/A | 0.00 | -0.03 | -0.09 | 0.27 |
|---|
| Revenue (ttm):
| 6.12M | 22.60B | 42.21B | 57.60B | 13.93B |
|---|
| Gross Margin (ttm): | -0.04 | 0.79 | 0.71 | 0.81 | 0.72 |
|---|
| EBITDA (ttm): | -174.50M | 6.51B | 14.49B | 25.34B | 1.51B |
|---|
| Operating Margin (ttm):
| -28.56 | 0.22 | 0.28 | 0.32 | 0.13 |
|---|
| Net Income (ttm): | -174.74M | 4.63B | 6.78B | 10.52B | N/A |
|---|
| EPS (ttm): | -1.74 | 4.16 | 2.74 | 2.09 | 0.61 |
|---|
| P/E (ttm): | N/A | 12.35 | 18.82 | 13.93 | 18.43 |
|---|
| PEG (5 yr expected): | -0.14 | -5.72 | 4.12 | 4.82 | 1.51 |
|---|
| P/S (ttm): | 226.18 | 2.51 | 3.01 | 3.62 | 3.64 |
|---|
|
| LLY = Eli Lilly and Company | | GSK = GlaxoSmithKline plc | | PFE = Pfizer Inc. | | Industry = Biotechnology | |
| Biotechnology Companies Ranked By Sales | |
|---|
|
| Company | Symbol | Price | Change | Market Cap | P/E |
|---|
| Amgen Inc. | AMGN | 99.18 | -0.02 | 74.38B | 16.79 |
|---|
| Genentech, Inc. | "Private" |
|---|
| Biogen Idec Inc. | BIIB | 203.80 | -0.03 | 48.38B | 32.34 |
|---|
| Genzyme Corporation | "Private" |
|---|
| Merck Serono S.A. | "Private" |
|---|
| Gilead Sciences Inc. | GILD | 50.60 | -0.03 | 77.18B | 28.33 |
|---|
| MedImmune, L.L.C. | "Private" |
|---|
| Life Technologies Corporation | LIFE | 74.21 | -0.00 | 12.77B | 31.42 |
|---|
| Teva Pharmaceutical Industries Limited | TEVA | 39.30 | -0.01 | 33.48B | 19.62 |
|---|
| Sandoz International GmbH | "Private" |
|---|
|
| Generic Drugmakers Ranked by Sales | |
|---|
|
| Company | Symbol | Price | Change | Market Cap | P/E |
|---|
| Actavis, Inc. | ACT | 123.71 | -0.02 | 15.80B | N/A |
|---|
| Ranbaxy Laboratories Limited | "Private" |
|---|
| Mylan, Inc. | MYL | 31.27 | -0.02 | 11.92B | 20.89 |
|---|
| Pfizer Inc. | PFE | 29.10 | -0.01 | 206.41B | 13.93 |
|---|
| Johnson & Johnson | JNJ | 84.86 | -0.02 | 238.36B | 23.05 |
|---|
| GlaxoSmithKline plc | GSK | 51.48 | -0.02 | 124.68B | 18.82 |
|---|
| Sanofi | SNY | 53.40 | -0.02 | 141.34B | 26.32 |
|---|
| Novartis AG | NVS | 71.90 | -0.02 | 176.67B | 18.25 |
|---|
| Roche Holding AG | RHHBY | 61.90 | -0.01 | 210.08B | 20.72 |
|---|
| AstraZeneca PLC | AZN | 50.19 | -0.02 | 62.74B | 11.10 |
|---|
|
| Drugmakers Ranked By Sales | |
|---|
|
| Company | Symbol | Price | Change | Market Cap | P/E |
|---|
| Abbott Laboratories | ABT | 36.21 | -0.03 | 56.45B | 11.04 |
|---|
| Bristol-Myers Squibb Company | BMY | 46.05 | -0.02 | 75.64B | 52.15 |
|---|
|
| News on Direct Competitors | |
|---|
- LLY
- Lilly and Incyte Announce Baricitinib Efficacy and Safety Data from the Open-Label, Long-Term Extension of the Phase 2b JADA Study in Patients with Rheumatoid Arthritis at noodls Thu, Jun 13
- LLY
- Lilly and Incyte Announce Baricitinib Efficacy and Safety Data from the Open-Label, Long-Term Extension of the Phase 2b JADA Study in Patients with Rheumatoid Arthritis at noodls Thu, Jun 13
- GSK
- Transaction in Own Shares at noodls Wed, Jun 12
- GSK
- Director/PDMR Shareholding at noodls Wed, Jun 12
- GSK
- Director/PDMR Shareholding at noodls Wed, Jun 12
- PFE
- Pfizer Obtains $2.15 Billion Settlement from Teva and Sun for Infringement of Protonix® Patent at noodls Wed, Jun 12
- GSK
- Transaction in Own Shares at noodls Tue, Jun 11
- GSK
- GSK statement regarding 2010 Nature Medicine study at noodls Tue, Jun 11
- PFE
- Merck & Co., Inc. and Pfizer Enter Worldwide Collaboration Agreement to Develop and Commercialize Ertugliflozin, an Investigational Medicine for Type 2 Diabetes at noodls Mon, Apr 29
- PFE
- Pfizer Presents Phase 3 Safety And Immunogenicity Data On Prevenar 13 In Adults Aged 18 To 49 Years at noodls Sun, Apr 28
- PFE
- Pain Therapeutics Reports Q1 2013 Financial Results at noodls Wed, Apr 24
- PFE
- Pfizer’s BOSULIF® (bosutinib) Receives Conditional Marketing Authorization From The European Commission at noodls Thu, Mar 28
- LLY
- QIAGEN enters into broad collaboration agreement with Lilly for the development and commercialization of companion diagnostics at noodls Thu, Feb 14
- LLY
- LILLY (ELI) & COMPANY - Amyvid Approved in European Union at noodls Wed, Jan 16
- LLY
- LILLY (ELI) & COMPANY - LLY Sets Dates for Financial Guidance & Q4 2012 Results at noodls Tue, Dec 18
All Headlines for these symbols... Currency in USD. | |
|
0.98%